title: Prevention of osteopenia induced with a gonadotropin-releasing hormone agonist in rats.
abstract: We investigated the effects of conjugated estrogens as an add-back replacement drug, incadronate sodium as a bisphosphonate, and alfacalcidol as a vitamin D(3) analog on femoral bone mineral density (BMD) and bone mineral content (BMC) in female rats chronically treated with the gonadotropin-releasing hormone (GnRH) agonist leuprorelin acetate. The chemical castration of the rats by the administration of GnRH agonist for 16 weeks reduced the BMD values to 92.3%, 91.3%, and 93.3% of those of the normal control animals in the whole femur, metaphysis, and diaphysis of the femur, respectively. The BMC value was decreased to 91.0% of that of the normal control animals by the chronic GnRH agonist treatment. However, a simultaneous 8-week administration of conjugated estrogens, bisphosphonate, and vitamin D(3) analog markedly augmented the BMC values to 110.3%, 110.1%, and 114.4%, respectively, of those in the rats treated with the GnRH agonist alone. These findings indicate that antiosteoporotic agents could be useful for preventing induced osteopenia under the careful monitoring of biochemical markers of osteoblastic activity or bone resorption and BMD or BMC in patients undergoing GnRH treatment.
authors.affiliation: Department of Endocrinology, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-5810, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Sakamoto
authors.forename: S
authors.initials: S
authors.lastname: Sassa
authors.forename: T
authors.initials: T
authors.lastname: Mitamura
authors.forename: H
authors.initials: H
authors.lastname: Kudo
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Yoshimura
authors.forename: Y
authors.initials: Y
authors.lastname: Zhou
authors.forename: T
authors.initials: T
authors.lastname: Kikuchi
authors.forename: H
authors.initials: H
authors.lastname: Shinoda
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D004164:Diphosphonates / Q000494:pharmacology*; D004958:Estradiol / Q000097:blood; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D005300:Fertility Agents, Female / Q000633:toxicity*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006887:Hydroxycholecalciferols / Q000494:pharmacology*; D016729:Leuprolide / Q000633:toxicity*; D007986:Luteinizing Hormone / Q000097:blood; D009929:Organ Size / Q000187:drug effects; D010052:Ovariectomy; D011859:Radiography; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D004164:Diphosphonates; D004966:Estrogens, Conjugated (USP); D005300:Fertility Agents, Female; D006887:Hydroxycholecalciferols; C071542:cimadronate; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide; C008088:alfacalcidol